Damiani (2020)
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration
10.1111/dth.13475
https://onlinelibrary.wiley.com/doi/10.1111/dth.13475
Treatment
Concomitant medication (Treated with biologics vs. Not received)
COVID-19 (severe/critical)
Odds ratio: 3.410 (0.210-54.550) Univariate analysis

Italy

Case-control study

Primary data collection

1193

1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls

PsO patients: Male, N (%) 811 (68); Age, mean ± SD, years 55 ± 12.7, BMI, mean ± SD, kg/m2 28.7 ± 2.5 PsO duration, mean ± SD, years 12.3 ± 9.1 among controls 54 801 subjects were COVID-19 positive, 16 042 were self-isolated (quarantined) at home, 11796 were hospitalized, 1236 were admitted to intensive care unit (ICU), and 10 222 died.

0


COVID-19 (severe/critical)

0

being admitted to ICU


Treatment

Concomitant medication

biologics

Not received

Treated with biologics


Odds ratio

3.410 (0.210-54.550)

No

No

No

none


none

Average

No